Kangmei Pharmaceutical Statistics

Total Valuation

Kangmei Pharmaceutical has a market cap or net worth of CNY 34.94 billion. The enterprise value is 34.41 billion.

Market Cap	34.94B
Enterprise Value	34.41B

Important Dates

The last earnings date was Monday, October 28, 2024.

Earnings Date	Oct 28, 2024
Ex-Dividend Date	n/a

Share Statistics

Kangmei Pharmaceutical has 13.86 billion shares outstanding. The number of shares has increased by 0.03% in one year.

Current Share Class	n/a
Shares Outstanding	13.86B
Shares Change (YoY)	+0.03%
Shares Change (QoQ)	-42.35%
Owned by Insiders (%)	0.00%
Owned by Institutions (%)	11.32%
Float	9.88B

Valuation Ratios

The trailing PE ratio is 136.72.

PE Ratio	136.72
Forward PE	n/a
PS Ratio	6.70
PB Ratio	4.96
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 57.37, with an EV/FCF ratio of -68.45.

EV / Earnings	134.67
EV / Sales	6.60
EV / EBITDA	57.37
EV / EBIT	123.95
EV / FCF	-68.45

Financial Position

The company has a current ratio of 1.43, with a Debt / Equity ratio of 0.03.

Current Ratio	1.43
Quick Ratio	0.77
Debt / Equity	0.03
Debt / EBITDA	0.36
Debt / FCF	-0.43
Interest Coverage	5.02

Financial Efficiency

Return on equity (ROE) is 3.71% and return on invested capital (ROIC) is 2.41%.

Return on Equity (ROE)	3.71%
Return on Assets (ROA)	1.21%
Return on Capital (ROIC)	2.41%
Revenue Per Employee	1.18M
Profits Per Employee	57,960
Employee Count	4,409
Asset Turnover	0.36
Inventory Turnover	1.60

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +51.34% in the last 52 weeks. The beta is 0.62, so Kangmei Pharmaceutical's price volatility has been lower than the market average.

Beta (5Y)	0.62
52-Week Price Change	+51.34%
50-Day Moving Average	1.94
200-Day Moving Average	1.93
Relative Strength Index (RSI)	65.81
Average Volume (20 Days)	684,522,935

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Kangmei Pharmaceutical had revenue of CNY 5.21 billion and earned 255.55 million in profits. Earnings per share was 0.02.

Revenue	5.21B
Gross Profit	665.09M
Operating Income	277.63M
Pretax Income	262.01M
Net Income	255.55M
EBITDA	545.02M
EBIT	277.63M
Earnings Per Share (EPS)	0.02

Full Income Statement

Balance Sheet

The company has 773.59 million in cash and 215.93 million in debt, giving a net cash position of 557.66 million or 0.04 per share.

Cash & Cash Equivalents	773.59M
Total Debt	215.93M
Net Cash	557.66M
Net Cash Per Share	0.04
Equity (Book Value)	7.08B
Book Value Per Share	0.51
Working Capital	2.10B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -413.90 million and capital expenditures -88.84 million, giving a free cash flow of -502.74 million.

Operating Cash Flow	-413.90M
Capital Expenditures	-88.84M
Free Cash Flow	-502.74M
FCF Per Share	-0.04

Full Cash Flow Statement

Margins

Gross margin is 12.76%, with operating and profit margins of 5.33% and 4.90%.

Gross Margin	12.76%
Operating Margin	5.33%
Pretax Margin	5.03%
Profit Margin	4.90%
EBITDA Margin	10.45%
EBIT Margin	5.33%
FCF Margin	-9.64%

Dividends & Yields

Kangmei Pharmaceutical does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-0.03%
Shareholder Yield	-0.03%
Earnings Yield	0.73%
FCF Yield	-1.44%

Stock Splits

The last stock split was on June 16, 2015. It was a forward split with a ratio of 2.

Last Split Date	Jun 16, 2015
Split Type	Forward
Split Ratio	2

Scores

Kangmei Pharmaceutical has an Altman Z-Score of 0.43. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	0.43
Piotroski F-Score	n/a